,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['bcsm', 'breast', 'destiny-breast04']
patricia lorusso of discusses destiny-breast04: challenges of assessing her2 status; t-dxd activity in her2-mutated cancers; mechanism of resistance. new standard of care for her2-low breast cancer. we need improved assays to identify who will benefit. #bcsm #asco22 
Medical oncologist @Intermountain, Director of Breast Oncology. Clinical research, quality improvement, cardio-oncology, provider wellness. All tweets my own.